Quick Facts: Therapeutic Domains

• Main Use: Prevention of pregnancy (contraception).
• Benefit: Provides an effective, long-acting method of birth control.
• Additional Use: May help manage specific medical conditions linked to the menstrual cycle.

---

What Depo Provera 150 Treats: Main Uses and Benefits

Depo Provera 150 (medroxyprogesterone acetate injectable suspension) is a prescription medication primarily used by females of reproductive potential to prevent pregnancy. This injectable option provides a long-term method of contraception administered every three months (13 weeks).

When used as directed, this treatment helps reduce the likelihood of pregnancy. The medication may also be a part of a therapeutic regimen to help manage certain medical conditions that are related to the menstrual cycle. These conditions may include specific types of anemia, endometriosis, and uterine fibroids. In some instances, Depo Provera 150 may also help reduce the severity of menstrual cramps and lessen menstrual blood flow over time, leading to the cessation of periods in some individuals.

Eligibility to Use Depo Provera 150

Depo Provera 150 (Medroxyprogesterone Acetate Injectable Suspension) is generally allowed for females of reproductive potential, including postmenarchal adolescent females. Eligibility rules are defined by regulatory authorities and must be strictly followed.

---

Contraindications (Who Must Not Use)

Use is strictly contraindicated (prohibited) for patients with the following conditions as documented in official labeling:

• Known or suspected pregnancy.
• A history of thromboembolic disorders or cerebral vascular disease.
• Known or suspected hormone-dependent malignancy of the breast.
• Severe liver disease whose function has not returned to normal.
• Undiagnosed vaginal bleeding (until a definitive diagnosis is established).

---

Age and Duration Restrictions

Population Group	Regulatory Status
Pediatric (Pre-Menarche)	Not indicated before menarche.
Geriatric (Post-Menopausal)	Not indicated and not studied.
Contraceptive Duration	Not recommended for use longer than 2 years, unless other methods are inadequate, due to concerns regarding bone mineral density (BMD) loss.

---

Pregnancy and Lactation

Use is contraindicated during pregnancy. For mothers who are exclusively breastfeeding, initiation of the injection is typically recommended during or after the sixth post-partum week.

The interaction profile for Depo Provera 150 (medroxyprogesterone acetate) is defined by its metabolic pathway and an additive pharmacodynamic risk. Medroxyprogesterone Acetate (MPA) is primarily cleared via hydroxylation involving the CYP3A4 enzyme, which is the basis for most documented drug-drug interactions, leading to mandated restrictions.

Interaction Type	Interacting Agents	Official Regulatory Description of Outcome
Pharmacokinetic (CYP3A4)	Strong CYP3A Inducers (e.g., Rifampin, Phenytoin)	Expected to decrease MPA serum concentration, potentially leading to reduced efficacy. Co-administration should be avoided.
	Strong CYP3A Inhibitors (e.g., Ketoconazole, Ritonavir)	Expected to increase MPA serum concentration. Co-administration should be avoided.
	Aminoglutethimide	May significantly depress serum concentrations of MPA.
Pharmacodynamic	Drugs that reduce Bone Mineral Density (e.g., Corticosteroids, Anticonvulsants)	Co-administration creates an additional risk of Bone Mineral Density (BMD) loss.
Herbal/Supplement	St. John's Wort	Noted as a strong CYP3A inducer; expected to decrease contraceptive effectiveness.

The regulatory constraints established for Depo Provera 150 focus on avoiding concomitant use with agents that significantly modulate CYP3A4 activity to maintain predictable drug exposure. Diabetic patients also require careful monitoring during treatment due to the potential for observed changes in glucose tolerance associated with progestin use. No mandatory timing separation rules for administration are documented in the official labeling.

Depo Provera 150, containing medroxyprogesterone acetate (MPA), functions as a potent progesterone receptor agonist. Following intramuscular injection, the compound is slowly released, establishing sustained plasma concentrations. The primary biological targets include the hypothalamus, anterior pituitary gland, and reproductive tissues such as the endometrium and cervix.

In the central nervous system, MPA binding to progesterone receptors inhibits the synthesis and secretion of gonadotropin-releasing hormone (GnRH) in the hypothalamus. This upstream molecular action leads to a downstream cascade: a pronounced reduction in the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. This system-level decrease in gonadotropins suppresses follicular maturation and abolishes the mid-cycle LH surge, consequently inhibiting the physiological process of ovulation.

In peripheral tissues, MPA induces cellular changes in the uterine lining, transforming the proliferative endometrium into a secretory or atrophic state. Concurrently, it causes a significant increase in the viscosity and cellularity of the cervical mucus, creating a high-resistance barrier that physically impedes the transit of sperm through the cervical canal.

How to Use Depo Provera 150

The administration of Depo-Provera (medroxyprogesterone acetate injectable suspension) follows a standardized protocol. The medicine is supplied as a sterile aqueous suspension that must be vigorously shaken just prior to use to ensure the drug particles are uniformly distributed.

Administration Principles

Instruction	Detail
Route of Administration	Administered exclusively as a deep intramuscular (IM) injection into the gluteal or deltoid muscle.
Standard Dosing	A fixed 150 mg dose is used for the prevention of pregnancy. This dose is not typically adjusted based on the patient's body weight.
Re-injection Interval	The dose must be delivered once every 13 weeks (three months) to maintain the official schedule.

---

Procedural Constraints

The regimen is defined by specific timing rules. The initial injection must be given during the first 5 days of a normal menstrual period. Administration for postpartum patients requires timing within the first 5 days postpartum if not breastfeeding, or delayed until at or after the sixth postpartum week if exclusively breastfeeding. Subsequent injections must adhere to the 13-week interval. If the scheduled time is exceeded, the patient must be confirmed to not be pregnant before the injection is given.

The same 150 mg dose and 13-week schedule apply to postmenarchal adolescents as they do to adults. Regarding long-term use, the medicine is generally not recommended for continuous use exceeding two years unless alternative contraceptive methods are considered inadequate. This defines a limiting factor for the treatment duration.

Research evidence / Overview of studies for Depo Provera 150

Evidence for Use in Preventing Pregnancy (Contraception)

Research examined this compound for use in preventing pregnancy. The studies conducted were primarily clinical trials, which was studied for its effect on preventing pregnancy. The overall findings describe patterns observed in these studies where the compound was studied in relation to pregnancy incidence rates.

In observational settings evaluating daily-life functioning, data show patterns related to outcomes reflecting daily functioning or activity level while using the compound. These studies explored short-term changes in a population where pregnancy was not desired. Research also examined continuation rates across different methods and formulations. Evidence contributes to understanding how this method performs under the specific conditions under which these studies were conducted.

Regarding other systemic or functional imbalance outcomes, research examined patterns of bone mineral density (BMD) changes during the study period. Longitudinal studies reported these patterns while using the injection, followed by a trend toward recovery after use ceased. The extent of BMD recovery after discontinuation remains unclear, and the evidence quality varies across studies regarding long-term observations. There is limited information for long-term outcomes beyond the follow-up durations that were limited in the initial studies.

Evidence for Non-Contraceptive Therapeutic Uses

This area will outline the clinical research—including controlled trials and systematic reviews—that has examined the medicine’s use for managing specific conditions related to the menstrual cycle, such as heavy menstrual bleeding and symptoms associated with endometriosis.

Long-Term Follow-up and Durability of Study Outcomes

This heading will summarize the long-duration studies that track patient outcomes over several years, focusing on what research has explored regarding the time required for a return to fertility after discontinuation and the assessment of bone mineral density (BMD) over time.

Evidence in Special Study Populations

This section will describe the clinical investigations that have specifically examined post-menarcheal adolescents and post-partum women, outlining the distinct outcomes measured in these groups where developmental status or concurrent physiological changes were relevant study factors.

What is Still Uncertain About the Research Base

This concluding section will synthesize the main evidence gaps noted in regulatory and research summaries, clarifying the areas where long-term data are limited, where findings remain heterogeneous, and where more focused investigation is needed.

Evidence for Conditions Characterized by Symptoms Related to Endometriosis

This compound was also studied for use in conditions characterized by fluctuating or episodic manifestations, such as those associated with endometriosis. Research explored its application in conditions involving periods of heightened symptoms, focusing on patient-reported outcomes describing perceived discomfort.

The findings indicate patterns related to measured changes in outcomes related to physical discomfort, and patient-reported outcomes describing perceived discomfort. Studies monitored how symptoms evolved in the observed populations, and research suggests patterns of measured changes in these outcomes in some individuals. Findings help contextualize how patients reported their experience during the study period.

However, subgroup findings are uncertain, and data for certain groups remain insufficient. Comparative evidence is lacking when evaluating against all other potential management strategies. Research provides context but not individual predictions; the evidence highlights what is known—and what is still uncertain—about the measured outcomes in conditions involving periods of heightened symptoms. Long-term effects on functional limitations are not fully established.

Key Studies & References

1. Medroxyprogesterone Injection: MedlinePlus Drug Information
2. Long-acting reversible contraception: systematic review and guidelines on clinical and cost effectiveness

Common questions about Depo Provera 150 (FAQ)

Q: Is Depo Provera 150 considered the same type of birth control as a pill or patch?

A: Official product information describes this medicine as a progestin-only injection. This means it only contains one hormone and works without estrogen, unlike many combination hormonal contraceptives. It is also classified as a long-acting reversible contraceptive (LARC) because it is administered once every three months, distinguishing it from daily or weekly methods.

Q: How long after stopping Depo Provera 150 is typical for a woman's regular menstrual cycle to return?

A: Official regulatory information indicates that a return to a regular menstrual cycle often occurs within 9 to 12 months after the last injection. It is important to note that this is an average observation from studies, and the time required can vary widely among individuals.

Q: Can Depo Provera 150 be used for purposes other than preventing pregnancy?

A: Yes. According to regulatory documents, the medicine is approved not only for preventing pregnancy but also for the management of pain associated with endometriosis. The medicine is approved for specified conditions.

Q: Why do some people experience weight gain while receiving Depo Provera 150?

A: Weight gain is noted in regulatory documents as a common side effect. Studies suggest this observation may be related to the drug's minor cortisol-like activity, which can sometimes lead to increased appetite or fluid retention in some individuals.

Q: Is the return to fertility after stopping Depo Provera 150 different for every person?

A: Yes. Official patient information states that while fertility is expected to return after stopping the injection, the amount of time this takes is highly variable from one individual to the next. This highlights why individual follow-up is important after discontinuation.

Q: Do regulatory documents describe the effectiveness rate of Depo Provera 150?

A: Yes. Official documentation indicates that the injection is highly effective at preventing pregnancy. With perfect use (always on schedule), it is considered over 99% effective. Its effectiveness rate in typical use is estimated to be around 96%, reflecting its high efficacy as described in studies.

Q: Does Depo Provera 150 have a Black Box Warning, and what does it concern?

A: Yes. The medicine carries a formal Boxed Warning (sometimes referred to as a Black Box Warning) in its official labeling. This critical safety alert concerns the potential for loss of bone mineral density (BMD), a risk that increases the longer the medicine is used.

Q: How quickly does Depo Provera 150 start working after the first injection?

A: According to the official dosing schedule, the injection is considered immediately effective if it is administered within the first five to seven days after the start of a menstrual period. If the injection is given at any other time, use of a back-up contraceptive method is specified for the first seven days.

Q: Are there any specific lifestyle factors (like smoking) that may affect the use of Depo Provera 150?

A: Official warnings note that certain factors may increase the risk of serious side effects. For example, being a smoker is an identified risk factor that can increase the potential for blood clots while using this medicine.

Q: What is the role of progesterone in the human body, and how does this relate to the drug?

A: Progesterone is a natural hormone produced by the female body. The drug contains a synthetic version of this hormone (called a progestin) that works in three ways: it prevents ovulation, thickens cervical mucus to create a barrier to sperm, and thins the uterine lining.

Q: Is Depo Provera 150 known to be affected by antibiotics?

A: Most common antibiotics do not affect the effectiveness of this injection. However, the official drug interaction summary highlights that specific types of antibiotics that are strong CYP3A4 enzyme inducers (such as rifampin) can lower the concentration of the medicine in the blood, potentially making it less effective.

Q: Is it possible for the Depo Provera 150 injection site to become painful or bruised?

A: Yes. Official prescribing information lists Injection Site Reactions as a recognized adverse event associated with the medicine. If severe or persistent pain, redness, or bruising occurs at the site, healthcare guidance is generally recommended.

Q: Does the injection contain preservatives or ingredients other than the active drug?

A: Yes. While the active ingredient is medroxyprogesterone acetate, the injectable suspension also contains various inactive ingredients. These include compounds such as polyethylene glycol 3350, sodium sulfate anhydrous, and a preservative.

Q: Does the drug have any known effects on cholesterol levels?

A: Yes. Official studies and prescribing information indicate that the use of this medicine may cause changes in lipid profiles (cholesterol levels). This has been observed to sometimes include a decrease in the levels of High-Density Lipoprotein (HDL) cholesterol.

Q: Is Depo Provera 150 intended as an emergency contraceptive?

A: No. According to the official indications for use, this medicine is a long-acting reversible contraceptive (LARC) that is intended to prevent pregnancy over three months. It is not formulated or intended for use as an emergency contraceptive after unprotected sex.

Storage and Disposal Requirements for Depo-Provera 150 mg/mL

Storage and disposal of Depo-Provera 150 (medroxyprogesterone acetate injectable suspension) must strictly follow conditions outlined in regulatory labeling.

---

Storage Conditions

Storage Requirement	Condition
Temperature	Store at controlled room temperature (20 to 25 C / 68 to 77 F).
Restrictions	Do not freeze and do not store above 30 C.
Protection	Must be protected from light; store in the original carton.
Handling	Vials must be stored upright.

---

Handling and Disposal

The product must be kept out of reach of children.

Unused or expired product must be disposed of according to local regulations, which may include utilizing a drug take-back program.